Claims Scope:

Patent issued March 28, 2023. 

 

Sequence-specific Composition & Method claims 

– lentiviral vector (claims 1, 39, 56)  

– treating cells infected with HIV (claims 12, 49, 67) 

– treating HIV infection (claims 26, 81)  

– lentiviral particle (claims 5, 42, 60) 

-modified CD4 Cell (claims 8, 46, 63) 

– sequence specific limitations include: 

1. SEQ ID NO: 2 and SEQ ID NO:108  (Vif and Tat microRNAs) (claim 1; 12; 26; 5; 8), 

1. two of SEQ ID NO: 97 (CCR5 guide seq), SEQ ID NO: 6 (Vif guide seq), and SEQ ID NO: 7 (Tat guide seq) (claim 1; 12; 26; 5; 8),  

1. SEQ ID NO:1, SEQ ID NO: 2, and SEQ ID NO: 108 (CCR5, Vif, and Tat microRNAs) (claim 39; 49; 42; 46);  

1. at least two of SEQ ID NO:1, SEQ ID NO: 2, and SEQ ID NO: 108 (claim 56; 67; 81; 60; 63); and  

1. SEQ ID NO: 97, SEQ ID NO: 6, and SEQ ID NO: 7 (claim 56; 67; 81; 60; 63) 

(with or without sequence identity limitation (e.g., at least 80% or 90% or 95%)).